Skip to main content
SpringerLink
Log in

ICIs increase risk of grade 3–4 AEs in patients with solid tumours

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials Lancet Oncology : 25 Nov 2023. Available from: URL: https://doi.org/10.1016/S1470-2045(23)00524-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICIs increase risk of grade 3–4 AEs in patients with solid tumours. Reactions Weekly 1986, 11 (2023). https://doi.org/10.1007/s40278-023-51316-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-51316-8

Search

Navigation